Movement Alert｜CSPC Pharmaceutical Rises 3.08% in Regular Trading, Innovative Drug Combo Granted Breakthrough Therapy Designation for HER2-Positive Breast Cancer

Market Focus07-15

On July 15, CSPC Pharmaceutical rose 3.08% in regular trading, trading at HKD 8.3/share, with turnover of HKD 114 million.

On the news front, the company announced on July 14 that its self-developed albumin-bound docetaxel injection combined with annituzumab has been granted Breakthrough Therapy Designation by China's National Medical Products Administration. The proposed indication is first-line treatment of unresectable or metastatic HER2-positive adult breast cancer, providing an accelerated regulatory pathway for the combination therapy.

Additionally, Huatai-PineBridge Fund increased its holdings by 7.368 million shares on July 10 at approximately HKD 8.14 per share, totaling about HKD 59.96 million. The company also received a USD 25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for developing novel long-acting peptide drugs, signaling steady research progress. Multiple positive catalysts converged to boost market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106323255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106323255","market":"us","top_or_hot":-1,"title":"Movement Alert｜CSPC Pharmaceutical Rises 3.08% in Regular Trading, Innovative Drug Combo Granted Breakthrough Therapy Designation for HER2-Positive Breast Cancer","media":"Market Focus","content":"<p><p>On July 15, CSPC Pharmaceutical rose 3.08% in regular trading, trading at HKD 8.3/share, with turnover of HKD 114 million.</p><p>On the news front, the company announced on July 14 that its self-developed albumin-bound docetaxel injection combined with annituzumab has been granted Breakthrough Therapy Designation by China's National Medical Products Administration. The proposed indication is first-line treatment of unresectable or metastatic HER2-positive adult breast cancer, providing an accelerated regulatory pathway for the combination therapy.</p><p>Additionally, Huatai-PineBridge Fund increased its holdings by 7.368 million shares on July 10 at approximately HKD 8.14 per share, totaling about HKD 59.96 million. The company also received a USD 25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for developing novel long-acting peptide drugs, signaling steady research progress. Multiple positive catalysts converged to boost market sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC Pharmaceutical Rises 3.08% in Regular Trading, Innovative Drug Combo Granted Breakthrough Therapy Designation for HER2-Positive Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC Pharmaceutical Rises 3.08% in Regular Trading, Innovative Drug Combo Granted Breakthrough Therapy Designation for HER2-Positive Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, CSPC Pharmaceutical rose 3.08% in regular trading, trading at HKD 8.3/share, with turnover of HKD 114 million.</p><p>On the news front, the company announced on July 14 that its self-developed albumin-bound docetaxel injection combined with annituzumab has been granted Breakthrough Therapy Designation by China's National Medical Products Administration. The proposed indication is first-line treatment of unresectable or metastatic HER2-positive adult breast cancer, providing an accelerated regulatory pathway for the combination therapy.</p><p>Additionally, Huatai-PineBridge Fund increased its holdings by 7.368 million shares on July 10 at approximately HKD 8.14 per share, totaling about HKD 59.96 million. The company also received a USD 25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for developing novel long-acting peptide drugs, signaling steady research progress. Multiple positive catalysts converged to boost market sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1106323255","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106323255","pubTimestamp":1784080138,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, CSPC Pharmaceutical rose 3.08% in regular trading, trading at HKD 8.3/share, with turnover of HKD 114 million.On the news front, the company announced on July 14 that its self-developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"异动提醒|石药集团常规交易涨3.08%，创新药组合获HER2阳性乳腺癌突破性疗法认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On July 15, CSPC Pharmaceutical rose 3.08% in regular trading, trading at HKD 8.3/share, with turnover of HKD 114 million.On the news front, the company announced on July 14 that its self-developed albumin-bound docetaxel injection combined with annituzumab has been granted Breakthrough Therapy Designation by China's National Medical Products Administration. The proposed indication is first-line treatment of unresectable or metastatic HER2-positive adult breast cancer, providing an accelerated regulatory pathway for the combination therapy.Additionally, Huatai-PineBridge Fund increased its holdings by 7.368 million shares on July 10 at approximately HKD 8.14 per share, totaling about HKD 59.96 million. The company also received a USD 25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for developing novel long-acting peptide drugs, signaling steady research progress. Multiple positive catalysts converged to boost market sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106323255","isCrawlerRequest":true}